<html>
<head>
<title>ACP Alpha Blocker Monotherapy</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
</head>

<body bgcolor="B6b6b6">
<table width="777" border="0" cellpadding="0" cellspacing="0" bgcolor="214d7b" align="center">
  <tr> 
    <td height="64" valign="top" colspan="2"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="000000" align="center">
        <tr> 
          <td width="750" height="50" valign="middle"> 
            <div align="center"> 
              <p><a name="Top"></a><img name="APMtitle" src="../Assets/ABMtitle.gif" width="660" height="50" border="0" alt=""></p>
            </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="26" width="54"></td>
    <td valign="top" width="723" height="26"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="37"><a href="SS_ABM.html"><img src="../Assets/ACP1.gif" width="165" height="37" align="baseline" name="Short_Summary" border="0"></a><a href="ACP_ABM.html"><img src="../Assets/ACP2.gif" width="142" height="37" name="ACP" border="0"></a><a href="CE_ABM.html"><img src="../Assets/ACP3.gif" width="140" height="37" name="Clinical_Evidence" border="0"></a><a href="JNC6_ABM.html"><img src="../Assets/ACP4.gif" width="77" height="37" name="JNC_VI" border="0"></a><a href="PM_ABM.html"><img src="../Assets/ACP5.gif" width="78" height="37" name="PubMed" border="0"></a><a href="VA_ABM.html"><img src="../Assets/ACP6.gif" width="121" height="37" border="0"></a></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="44" width="54"></td>
    <td valign="top" height="44"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="723" height="38"><img src="../Assets/ACPheader.gif" width="330" height="50" align="baseline"><img src="../Assets/ACPheader2.gif" width="393" height="50" align="baseline"></td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="469" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0">
        <tr> 
          <td width="746" height="469" bgcolor="ffffff"> 
            <div align="center"><br>
              <table width="90%" border="0">
                <tr> 
                  <td colspan="2"> <p class="BEsection"><font color="#3399CC">Therapeutics</font></p>
                    <table width="100%" border="0">
                      <tr> 
                        <td bgcolor="#6699CC"><b><font size="4"><a name="antihypertensivetreatmentmayhavereducedtherateofdementiainolderpatientswithisolatedsystolichypertension"></a><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000><font 
      class=pageboldgrn color=#009982><font 
      class=abstitle><b><font color="#333333">Review: Intensive blood-pressure 
                          control and drugs reduce morbidity and mortality in 
                          hypertension and diabetes mellitus</font></b></font></font></font></font></b></td>
                      </tr>
                    </table>
                    <p class="AbsTitl"><font class="textblack" color="#333333"><font 
      class=pageboldgrn><b><font face="Arial, Helvetica, sans-serif" size="3">ACP 
                      Journal Club. 2001 Mar-Apr;134:48.</font></b></font></font></p>
                    <p><font class="sourcecitation" face="Arial, Helvetica, sans-serif" size="3">Grossman 
                      E, Messerli FH, Goldbourt U. <b>High blood pressure and 
                      diabetes mellitus. Are all antihypertensive drugs created 
                      equal?</b> Arch Intern Med. 2000 Sep 11;160:2447-52.</font></p>
                    <hr size=2 color=#3399CC> <p class="AbsHd"><font color="#3399CC">Question</font></p>
                    <p class="AbsTxt"><font class=textblack color=#000000><font class="pageboldgrn">In 
                      patients with hypertension and diabetes mellitus, what is 
                      the effectiveness of various antihypertensive treatments?</font></font></p>
                    <p class="AbsHd"><font color="#3399CC">Data sources</font></p>
                    <p class=abstxt><font class="textblack" color="#000000">Studies 
                      were identified by searching MEDLINE (to June 1999) with 
                      the terms diabetes mellitus, hypertension, blood pressure, 
                      treatment, and therapy. Bibliographies of relevant studies 
                      were also checked.</font><font class="textblack" color="#000000" size="2"></font></p>
                    <p></p>
                    <p class="AbsHd"><font color="#3399CC">Study selection</font></p>
                    <p class=abstxt><font class="textblack" color="#000000">English-language 
                      studies were selected if they were randomized controlled 
                      trials &gt; 12 months of duration that compared the effects 
                      of active drug treatments with placebo on morbidity and 
                      mortality in patients with hypertension and diabetes mellitus. 
                      </font><font class="textblack" color="#000000" size="2"> 
                      </font></p>
                    <p class="AbsHd"><font color="#3399CC">Data extraction</font></p>
                    <p class=abstxt><font class="textblack" color="#000000">Data 
                      were extracted on patient characteristics, follow-up period, 
                      blood pressure, rate of patients continuing to receive monotherapy, 
                      and cardiovascular morbidity and mortality. </font></p>
                    <p class="AbsHd"><font color="#3399CC">Main results</font></p>
                    <p class=abstxt><font class="textblack" color="#000000">8 
                      studies (5244 patients) met the selection criteria. 3 studies 
                      compared 2 active treatments, 1 study reported the effects 
                      of intensive blood-pressure lowering, and 3 studies compared 
                      active treatment with placebo. In 6 studies, mean ages ranged 
                      between 55 and 71 years; in 2 studies, patients were &gt;60 
                      years of age. Follow-up duration ranged between 2 and 8 
                      years. Intensive blood-pressure control reduced cardiovascular 
                      morbidity and mortality. One study showed that the calcium 
                      antagonist nisoldipine increased the incidence of fatal 
                      or nonfatal myocardial infarction more than did the angiotensin-converting 
                      enzyme (ACE) inhibitor enalapril maleate (11% vs 2%, relative 
                      risk increase 4%, 95% CI 1 to 11, number needed to harm 
                      12, CI 7 to 23). In the 3 studies that compared active treatment 
                      with placebo, a diuretic (chlorthalidone) and a calcium 
                      antagonist (nitrendipine) reduced cardiac end points, stroke, 
                      and total mortality. Comparisons between antihypertensive 
                      drugs were not possible because study populations differed. 
                      Except for nisoldipine, adverse events did not differ among 
                      drugs. </font></p>
                    <p class="AbsHd"><font color="#3399CC">Conclusion</font></p>
                    <p class=abstxt><font class="textblack" color="#000000">Intensive 
                      blood-pressure control reduces cardiovascular morbidity 
                      and mortality in patients with hypertension and diabetes 
                      mellitus regardless of which of 4 classes of antihypertensive 
                      drugs (low-dose diuretics, Î²-blockers, ACE inhibitors, 
                      and calcium antagonists) is used as first-line therapy. 
                      </font></p>
                    <hr size=2 color=#3399CC> <p class=grant><font class="textblack" color="#000000">Sources 
                      of funding: Various pharmaceutical companies.</font></p>
                    <p class=reprint><font class="textblack" color="#000000">For 
                      correspondence: Dr. F.H. Messerli, Ochsner Clinic, 1514 
                      Jefferson Highway, New Orleans, LA 70121, USA. FAX 504-842-4220. 
                      </font><font class="textblack" color="#000000" size="2"></font></p>
                    <p class="AbsFootn">*See <a href="../Assets/Glossary2.html" target="_blank">Glossary</a> 
                    </p>
                    <hr size=2 color=#3399CC> <p class="AbsHd"><font color="#3399CC">Commentary</font></p>
                    <p class=cmtxt><font class="textblack" color="#000000">Achieving 
                      tight blood-pressure control in patients with diabetes requires 
                      drug therapy, with most patients needing combination drug 
                      therapy (1). The choice of agent has been complicated by 
                      conflicting evidence of efficacy and safety. The review 
                      by Grossman and colleagues shows that currently used agents 
                      are more effective than is placebo for lowering cardiovascular 
                      risk in patients with diabetes and hypertension. </font></p>
                    <p class=cmtxt><font class="textblack" color="#000000">Does 
                      this mean that these agents are equivalent? Differences 
                      among agents are better assessed in head-to-head comparisons. 
                      The results of the review are consistent with a recently 
                      published meta-analysis (2) that reviewed the same 4 randomized 
                      trials comparing ACE inhibitors with calcium antagonists, 
                      diuretics, and Î²-blockers. In 3 trials, ACE inhibitors 
                      lowered the risk for cardiovascular events (relative risk 
                      reduction [RRR] 51%, CI 33 to 64) and all-cause mortality 
                      more than did other agents (RRR 62%, CI 13 to 62) with no 
                      effect on the risk for stroke. The fourth trial (the U.K. 
                      Prospective Diabetes Study) may not have had sufficient 
                      power to show differences between ACE inhibitors and Î²-blockers 
                      (3). These reports show that ACE inhibitors are similar 
                      to, if not better than, other antihypertensive drug classes 
                      for patients with diabetes. </font></p>
                    <p class=cmtxt><font class="textblack" color="#000000">Should 
                      ACE inhibitors be used as first-line treatment in patients 
                      with diabetes and hypertension? Treatment with ramipril 
                      in patients with diabetes and hypertension lowers cardiovascular 
                      risk by 25% (CI 12 to 36) (4), a reduction beyond its antihypertensive 
                      effect. This evidence supports the consideration of ACE 
                      inhibitors in all patients with diabetes and hypertension. 
                      Whatever the choice of agent, patients with diabetes and 
                      their clinicians should choose tight blood-pressure control. 
                      </font></p>
                    <p class=cmauth><font class="textblack" color="#000000">Victor 
                      M. Montori, MD</font></p>
                    <p class=cmauthaff><font class="textblack" color="#000000">Mayo 
                      Clinic</font></p>
                    <p class=cmauthaff><font class="textblack" color="#000000">Rochester, 
                      Minnesota, USA</font><font class="textblack" color="#000000" size="2"></font></p>
                    <hr size=2 color=#3399CC> <br> <table width="100%" border="0">
                      <tr> 
                        <td bgcolor="#6699CC"><font class="textblack" color="#000000"><b>References</b></font></td>
                      </tr>
                    </table>
                    <p class=refhd><font class="textblack" color="#000000">1. 
                      <b>U.K. Prospective Diabetes Study Group.</b> Tight blood 
                      pressure control and risk of macrovascular and microvascular 
                      complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13. 
                      </font></p>
                    <p class=ref id=ACPJC-2001-134-2-048-r2><font class="textblack" color="#000000">2. 
                      <b>Pahor M, Psaty BM, Alderman MH, et al.</b> Therapeutic 
                      benefits of ACE inhibitors and other antihypertensive drugs 
                      in patients with type 2 diabetes. Diabetes Care. 2000;23:888-92. 
                      </font></p>
                    <p class=ref id=ACPJC-2001-134-2-048-r3><font class="textblack" color="#000000">3. 
                      <b>U.K. Prospective Diabetes Study Group.</b> Efficacy of 
                      atenolol and captopril in reducing risk of macrovascular 
                      and microvascular complications in type 2 diabetes: UKPDS 
                      39. BMJ. 1998;317:713-20. </font></p>
                    <p class=ref id=ACPJC-2001-134-2-048-r4><font class="textblack" color="#000000">4. 
                      <b>Heart Outcomes Prevention Evaluation Study Investigators.</b> 
                      Effects of ramipril on cardiovascular and microvascular 
                      outcomes in people with diabetes mellitus: results of the 
                      HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9. 
                      </font><font class="textblack" color="#000000" face="arial, helvetica, sans-serif"> 
                      </font></p>
                    <p class="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><font 
      class=copyrightblue face="arial, sans-serif" color=#3399cc 
      size=1>Copyright Â©2001 American College of Physicians  American Society 
                      of Internal Medicine</font> </font></font></p>
                    <p class="CmRef" align="right">&nbsp;</p></td>
                </tr>
                <tr> 
                  <td width="87%"><div align="center"><strong>Reprinted with permission<br>
                      &copy; American College of Physicians- American Society 
                      of Internal Medicine</strong></div></td>
                  <td width="13%"><div align="right"><a href="#Top"><img src="../Assets/Top.gif" width="76" height="37" border="0"></a></div></td>
                </tr>
              </table>
              <p class="BEsection" align="center">&nbsp;</p>
              </div>
          </td>
        </tr>
      </table>
    </td>
  </tr>
  <tr> 
    <td height="28" width="54"></td>
    <td valign="top"> 
      <table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="#55C6C6">
        <tr> 
          <td width="723" height="28" bgcolor="528ece"> 
            
          </td>
        </tr>
      </table>
    </td>
  </tr>
</table>
</body>
</html>